Bespak launches Syrina 2.25 auto injector
The new Syrina 2.25 is one of the most compact versions of auto-injector available today utilising the standard 2.25 mL PFS, based on Bespak’s proprietary VapourSoft technology.
Bespak has launched Syrina 2.25 at PDA Europe 2015. Moreover, Steven Kaufman, Global Business Development Lead at the company, will chair a 1-day specialized industry discussion on innovative combinational products at a workshop taking place during the renowned PDA Europe 2015 Universe of Pre-filled Syringes & Injection Devices in Vienna, Austria.
Key focus areas to be addressed at the workshop include advanced technologies in the field of self-injection devices, ranging from auto, pen, bolus and wearable-injectors through to pumps. Above all, the event will focus on how innovation in the design of combination products will help overcome industry challenges, improve compliance and enhance the patient experience.
Moreover, the discussion will focus on insights into how primary containers, such as prefilled syringes and cartridges, both in plastic and in glass form, can be effectively integrated into such devices. Overcoming challenges and implementing effective approaches for successfully taking combinational products to market also forms a significant part of the workshop’s agenda.
Leading biopharmaceutical companies and related suppliers are set to take part in the workshop and will share industry experiences and discuss the technology behind devices used in today’s growing field of combination products. Bespak has chosen this event to launch the latest addition to the Syrina product range, Syrina 2.25. This new product will highlight how flexible the technology is, directly addressing the need for higher volume and higher viscous solutions. The Syrina range of self-injection devices, which span assisted syringes with needle safety features through to fully functioning auto-injectors, all utilise Bespak’s proven VapourSoft powerpack system.
Commenting on Bespak’s involvement in chairing the workshop, Steven Kaufman commented: “We are pleased to have this opportunity to lead industry discussion on the transformational impact, for the drug delivery device sector and for patients, of innovation in the field of combinational products. Indeed, at Bespak, we are committed to the development of advanced, problem solving technology and therefore welcome this forum for sharing insights. The PDA is a great organization and provides us with an excellent forum.”
Remarking on the launch of Syrina 2.25, Steven Kaufman said: “We are also excited to unveil our newest addition to the Syrina offering. This new product will be available for exclusive demo in Vienna and to biopharmaceutical companies that would like to conduct studies to learn more about the technology first hand. We look forward to the Vienna event.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.